Javier de Castro's research while affiliated with Fundación Hospital de la Santísima Trinidad and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Objectives: To analyze the fatty acid profiles of erythrocyte total lipids from patients with advanced squamous cell lung carcinoma (SCC), lung adenocarcinoma (ADC), and small cell lung cancer (SCLC) and benign lung diseases (chronic obstructive pulmonary disease [COPD] and asthma) to reveal the fatty acids that could be used as lung cancer biomark...
New parameters that could be used as tumor markers for lung cancer would be valuable. Our aim was to analyze the fatty acid profiles of total lipids from erythrocytes and platelets from patients with advanced non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD) and asthma to reveal the fatty acids that could be used as N...
The phospholipid fatty acid profiles of erythrocytes and platelets from fifty patients with advanced non-small cell lung cancer were investigated using gas chromatography/mass spectrometry, followed by "ROC" curves analysis to gain novel biomarker information. Sialic acid and cytokeratins were also examined. Potentially useful fatty acid markers: E...
To analyse and compare the phospholipid and fatty acid composition of total lipids and the occurrence of lipid peroxidation and protein oxidation directly in erythrocytes or platelets from chronic obstructive pulmonary disease (COPD) and asthma patients.
Fifteen consecutive outpatients with COPD (all smokers) and asthma (non-smokers) recruited duri...
The formation of free radicals and lipid peroxidation products is linked both to carcinogenesis and tumor behavior. Blood samples from 50 patients with advanced (Stages III-IV) non-small cell lung cancer (NSCLC), and from 50 healthy volunteers were used for plasma beta-thromboglobulin (beta-TG) measurements, red blood cell (RBC) and platelet lipid...
Citations
... The non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers [1,2]. The lung adenocarcinoma (LUAD) is the most prevalent pathological subtype among NSCLC. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272588001771558-1442001452910_Q64/Jesus-Sanchez-Yaguee.jpg)
... Research indicates a signi cant elevation of LA and its metabolites in the serum of lung cancer patients compared to those with non-malignant pulmonary conditions [12]. Additionally, fatty acid pro les of erythrocytes and platelets have also shown potential as biomarkers for NSCLC, with LA being identi ed as a useful marker in platelets [13]. SFAs have also drawn attention concerning their role in lung cancer. ...
... Emerging evidence also suggests that advanced NSCLC is associated with modifications in phospholipid fatty acids from red blood cells and PLTs. 54 In this regard, De Castro et al. investigated the diagnostic role of fatty acid from erythrocytes and PLTs in 50 advanced NSCLC patients, 15 patients with chronic obstructive pulmonary disease (COPD), and 50 healthy individuals. Interestingly, this study revealed that PLT linoleic acid had higher diagnostic value in distinguishing cancer patients versus benign inflammatory diseases/healthy controls. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272580758208533-1441999725818_Q64/Angel-Hernandez-Hernandez.jpg)
... PUFA could convert into a variety of different pro-inflammatory mediators, such as leukotriene and prostaglandins under the catalysis of a series of enzymes [cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450) etc.], which promote inflammation and transmit signaling by receptor-mediated mechanisms (45). PUFA are also particularly sensitive to oxidative injury, the reduced lipids reflected an increased level of oxidative stress after CS exposure (46). Linoleic acid, α-Linolenic acid and palmitic acid had positive correlations with FEV 25 /FVC and FEV 50 / FVC, and negative correlations with IC, TLC and Cchord. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/811373835583489-1570458005887_Q64/Jose-Sardina-2.jpg)
... Currently, there are no validated biomarkers for diagnosis of new, persistent or recurrent HNSCC, and the evaluation of patients' blood can be an excellent alternative, since the sample is accessible and non-invasive, avoiding the need for biopsies. It has recently been shown that changes in phospholipids in the erythrocyte membrane and changes in rheological properties during the development of cancer can serve as biomarkers in the diagnosis of this pathology (de Castro et al. 2008;Sánchez-Rodríguez et al. 2015). Thus, in our study, we sought to investigate changes in the lipid and enzymatic profile that occur in erythrocytes in patients with HNSCC that can act as a new strategy for the non-invasive diagnosis of this type of cancer. ...
